MRNA vs INCY — Key Metrics
| Metric | MRNA (MODERNA INC) | INCY (INCYTE CORP) |
|---|---|---|
| Price | 192.57 | 121.35 |
| Market Cap | 76.88 Billion | 24.6 Billion |
| P/E (TTM) | -24.1 | 14.94 |
| P/B (Quarterly) | 3.237 | 4.151 |
| P/S (TTM) | 34.51 | 4.23 |
| Net Profit Margin (TTM) | -141.4 | 27.7 |
| Gross Margin (TTM) | 23.4 | 92.6 |
| ROE (TTM) | -39.2 | 29.6 |
| Revenue Growth YoY (TTM) | None | None |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
MRNA · MODERNA INC
Greatly Underperform
INCY · INCYTE CORP
Greatly Outperform
Recommendation Summary
Stock MRNA is projected to greatly underperform the market, stock INCY is projected to greatly outperform the market. Upfront Recommendation: INCY.
Financial Metrics
Prices delayed ~15 min
| MRNA | Metrics | INCY |
|---|---|---|
| $192.57 | Price | $121.35 |
| — | Market Capitalization | — |
| 34.51 | Price to Sales | 4.23 |
| 147.56 | Price to Gross Profit | 4.56 |
| 26.73 | Price to R&D | 11.44 |
| 13.22 | Price to Current Assets | 4.08 |